Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • projectdatasphere html home Accessed October br World Health

    2019-09-20

    projectdatasphere/html/home. Accessed: October 7, 2017.
    8. World Health Organization; International Agency for Research on Cancer. Global Cancer Observatory. Available at: globocan.iarc.fr. Accessed: November 27, 2016. 9. Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6):vi64-72.
    10. Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of met-astatic colorectal cancer. Ann Oncol 2014; 25:1346-55.
    11. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27: 672-80.
    12. Schmoll HJ, Cunningham D, Sobrero A, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: 6-NBDG double-blind, randomized phase III study (HORIZON III). J Clin Oncol 2012; 30:3588-95.
    13. Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 2014; 15:47.
    14. Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res 2015; 7:133-43. 15. Cheng H, Gammon D, Dutton TM, Piperdi B. Panitumumab-related hypomagnesemia in patients with colorectal cancer. Hosp Pharm 2009; 44: 234-8.
    Contents lists available at ScienceDirect
    Toxicology and Applied Pharmacology
    journal homepage: www.elsevier.com/locate/taap
    5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells 
    T
    Sara Ranjbara,b,c, Ruttiros Khonkarnd,f, Alexis Morenod, Hélène Baubichon-Cortayd, Ramin Miria, Mehdi Khoshneviszadeha,c, Luciano Sasoe, Najmeh Edrakia, Pierre Falsond, , Omidreza Firuzia, a Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran b Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran c Department of Medicinal Chemistry, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran d Drug Resistance & Membrane Protein (DRMP) Group, CNRS/Lyon I University UMR 5086 (MMSB), IBCP, 69367 Lyon, France e Department of Physiology and Pharmacology “Vittorio Erspamer”, Sapienza University of Rome, Italy f Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand
    Keywords:
    ABCB1
    ABCC1
    ABCG2
    Calcein AM
    Mitoxantrone 
    Multidrug resistance (MDR) in cancer cells is often associated with overexpression of ATP-binding cassette (ABC) transporters, including P-glycoprotein (P-gp/ABCB1), multidrug resistance-associated protein 1 (MRP1/ABCC1) and breast cancer resistance protein (BCRP/ABCG2). Modulators of these transporters might be helpful in overcoming MDR. Moreover, exploiting collateral sensitivity (CS) could be another approach for efficient treatment of cancer. Twelve novel 5-oxo-hexahydroquinoline derivatives bearing different aromatic substitu-tions at C4, while having 2-pyridyl alkyl carboxylate substituents at the C3 were synthesized and evaluated for MDR reversal activity by flow cytometric determination of rhodamine 123, calcein and mitoxantrone accu-mulations in P-gp, MRP1 and BCRP-overexpressing cell lines, respectively. Furthermore, to confirm the P-gp inhibitory activity, the effect of compounds on the reduction of doxorubicin's IC50 of drug-resistant human uterine sarcoma cell line, MES-SA/DX5, was evaluated. Compounds D6, D5 and D3 (bearing 3-chlorophenyl, 2,3-dichlorophenyl and 4-chlorophenyl substituents at C4 position of 5-oxo-hexahydroquinoline core) were the most potent P-gp, MRP1 and BCRP inhibitors, respectively, causing significant MDR reversal at concentrations of 1–10 μM. Additionally, D4 (containing 3-flourophenyl) was the most effective MRP1-dependent CS inducing agent. Overall, chlorine containing compounds D6, C4 and D3 were capable of significant inhibition of all 3 important efflux pumps in cancer cells. Moreover, D6 also induced CS triggered by reducing glutathione efflux. In conclusion, some of the 5-oxo-hexahydroquinoline derivatives are effective efflux pump inhibitors capable of simultaneously blocking 3 important ABC transporters involved in MDR, and represent promising agents to overcome MDR in cancer cells.